Rituximab does not seem to increase the risk for severe outcomes compared with other cold agglutinin disease (CAD)…
Andrea Lobo
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
Atypical symptoms, including persistent blue discoloration and skin lesions in the extremities, along with uncommon laboratory findings, delayed a…
Sanofi’s experimental therapy SAR445088 effectively blocks the classic complement pathway — a part of the immune system that’s implicated…
The rare case of a young woman with cold agglutinin disease (CAD) secondary to chickenpox, also known as varicella,…